Actualités sur Medikament

06.09.2022 – 10:15
Schweizerischer Nationalfonds / Fonds national suisse
Broad-based Swiss Covid-19 research
Bern (ots) - During the coronavirus pandemic, the Swiss National Science Foundation (SNSF) supported a total of 114 Covid-19 research projects, for which it used funding of over CHF 45 million. In the National Research Programme "Covid-19" (NRP 78), around 200 researchers are working in 28 projects with a total budget of CHF 20 million. Another research programme on Covid-19 is about to start. It was the first time the ...
plus
23.08.2022 – 11:36
Hovione
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
Lisbon, Portugal (ots/PRNewswire) - Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and ...
plus
16.08.2022 – 13:31
Medison Pharma
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
Petach Tikvah, Israel (ots/PRNewswire) - Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in ...
plus
01.08.2022 – 16:53
Rafa; ExCEEd Orphan
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
Jerusalem and Prague, Czech Republic (ots/PRNewswire) - Rafa Laboratories LTD. ("Rafa") and ExCEEd Orphan s.r.o ("ExCEEd") announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe ("CEE") and Israel. Under the agreement, and as part of its strategy to become an ...
plus
30.06.2022 – 13:01
Neuromod Devices Ltd
Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms
Dublin (ots/PRNewswire) - - Second large-scale trial shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire® - 91% of treatment compliant participants experienced improvement in tinnitus symptoms that sustained 12 months after treatment - 87.8% said they would recommend ...
plus
20.06.2022 – 06:30
News Direct
UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR
Liverpool England and Philadelphia USA (ots) - --News Direct-- SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to ...
plus
09.06.2022 – 08:01
MC2 Therapeutics
Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer
Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022. Professor Lars Iversen will be a key member of the Executive Team at MC2 ...
plus
08.06.2022 – 17:49
Medison Pharma
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma
Petach Tikvah, Israel (ots/PRNewswire) - KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly ...
plus
06.06.2022 – 13:00
Medison Pharma
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
Petach Tikvah, Israel (ots/PRNewswire) - Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries, including ...
plus
01.06.2022 – 10:01
TauRx Pharmaceuticals Ltd
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
Singapore (ots/PRNewswire) - - LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research - Safety profile is favourable and consistent with previous HMTM studies - TauRx will now pursue ...
plus
31.05.2022 – 14:55
Filterlex Medical
Filterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device
Caesarea, Israel (ots/PRNewswire) - Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications. Filterlex Medical Ltd., a cardiovascular medical device startup, announced today results from a first-in-human (FIH) study demonstrating the ...
plus
31.05.2022 – 13:01
Oxitec
Oxitec and the Government of Djibouti Announce New Multi-Year Partnership to Fight Invasive Malaria-Transmitting Mosquitoes Threatening the Horn of Africa
Oxford, England (ots/PRNewswire) - - With strong support from the Government of Djibouti, this program will pilot a new Friendly™ mosquito control technology to combat the growing threat to the region posed by the rapidly spreading malaria vector, Anopheles stephensi. - Oxitec will work hand-in-hand with the ...
plus
23.05.2022 – 13:27
Medison Pharma
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
Petach Tikvah, Israel (ots/PRNewswire) - The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients ...
plus
16.05.2022 – 09:01
Tethis S.p.A.
Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing
Milan (ots/PRNewswire) - The new platform will be presented at the next EACR Liquid Biopsy conference to be held in Bergamo, Italy, on May 24th-26th, 2022 Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a ...
plus
12.05.2022 – 13:01
POCARED Diagnostics; European Investment Bank
Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system
Rehovot, Israel (ots/PRNewswire) - - First EIB support for medtech investment in Israel - Financing to accelerate development of rapid testing system to improve infectious disease diagnosis and antibiotics stewardship - Automated phenotypic testing, revolutionizing infectious diseases diagnostics from sample to ...
plus
11.05.2022 – 10:01
Acousia Therapeutics GmbH
Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
Tübingen (ots) - Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule ...
plus
10.05.2022 – 14:55
Filterlex Medical
Filterlex Medical Successfully Completes First-In-Human Study for CAPTIS® Full-Body Embolic Protection Device
Caesarea, Israel (ots/PRNewswire) - Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS ...
plus
09.05.2022 – 10:45
Debiopharm International SA
Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
Berlin/Lausanne/Barcelona/Munich (ots) - New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika - an app-based DTx platform empowering people affected by cancer. Berlin-based digital health company Fosanis, the ...
plus
05.05.2022 – 10:02
Acousia Therapeutics GmbH
Hearing loss company Acousia Therapeutics: first patient with age-related hearing loss treated with ACOU085
Tübingen (ots) - ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in a Phase 1b clinical study in Germany. The pre-screening of patients matching the comprehensive in/exclusion criteria for the ongoing trial is almost ...
plus
26.04.2022 – 14:01
Novaliq GmbH
NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational ...
plus
19.04.2022 – 11:00
Bendit Technologies
BENDIT Technologies Receives U.S. Food and Drug Administration 510(k) Clearance of its Bendit 021" steerable microcatheter
Tel Aviv, Israel (ots/PRNewswire) - BENDIT Technologies, a company focused on the development of a steerable microcatheter platform, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Bendit21 microcatheter for treatment in the neuro, peripheral, and coronary ...
plus
14.04.2022 – 07:00
TauRx Pharmaceuticals Ltd
TauRx's late-stage clinical trial reaches new milestone
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed ...
plus
13.04.2022 – 17:08
Oxitec Ltd.
Oxitec's Malaria Program Receives New Investment to Expand to Pilot Phases in Two Malaria-Affected Regions
Oxford, England (ots/PRNewswire) - - Oxitec's team of experts will advance development and pilot validation of the Friendly™ mosquito platform to combat two malaria-spreading mosquitoes: the invasive Anopheles stephensi, predicted to cause urban malaria epidemics across Africa; and Anopheles albimanus, which is ...
plus
04.04.2022 – 15:00
News Direct
Lancer Dermatology Announces Partnership with Forefront Dermatology
Beverly Hills, CA (ots) - --News Direct-- Premier Beverly Hills-based dermatology practice, Lancer Dermatology, announced today that it has partnered with Forefront Dermatology, the largest physician-led single specialty group providing dermatological services in the United States with over 200+ dermatology practices. The collaboration with Forefront Dermatology will ...
plus
01.04.2022 – 09:00
Chiesi Farmaceutici S.p.A.
CHIESI GROUP CONTINUES GROWTH
Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...
plus
30.03.2022 – 15:00
Debiopharm International SA
VIVOSENSE ANNOUNCES CLOSING OF $25M SERIES A FINANCING
Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...
plus
30.03.2022 – 13:01
CartiHeal
FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects
Kfar Saba, Israel (ots/PRNewswire) - Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint CartiHeal Ltd, developer of implants for the treatment of cartilage and ...
plus
29.03.2022 – 12:05
Grünenthal Group
Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
plus
24.03.2022 – 08:00
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...
plus
08.03.2022 – 13:00
News Direct
Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
BOSTON, MA (ots) - --News Direct-- Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose ...
plus

Précédent12345678910Suivant